Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nefazodone

Next Previous
Drug Profile

Nefazodone

Alternative Names: BMY 13754; Dutonin; MJ 13754; MS 13754; Nefadar; SERZONE

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Menarini; Merck KGaA; Mitsubishi Pharma Corporation; Teva Pharmaceutical Industries
  • Class Antidepressants; Small molecules; Triazoles
  • Mechanism of Action Adrenergic receptor antagonists; Serotonin 2A receptor antagonists; Serotonin 5-HT2 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Major depressive disorder
  • Discontinued Panic disorder

Most Recent Events

  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 29 Jun 2004 Discontinued - Phase-II for Depression in Japan (PO)
  • 29 Jun 2004 Discontinued - Phase-III for Panic disorder in Europe (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top